What if a simple weekly injection could relieve worn knees better than years of patience and successive diets? Two phase III clinical trials conducted by Northwestern University, involving more than 1,000 participants in total, are challenging the certainties about obesity-related knee osteoarthritis. At the highest dose, retatrutide, an experimental injectable, achieved an average weight loss of about a quarter of body weight.
A quarter of body weight lost in just a few months
The numbers deserve attention. In these two phase III trials, participants who received the highest dose of retatrutide lost on average nearly a quarter of their body weight. Some, as noted by Dr. Thomas Schnitzer, the study’s lead author, shed as much as 45 kilograms, or even more.
To put this result in perspective, it is necessary to compare with existing treatments. Semaglutide and tirzepatide, two GLP-1 medications already available, target one or two hormonal receptors and typically produce weight loss of 10 to 20%. Retatrutide, by contrast, acts on three receptors at once, which largely explains this performance gap.
This difference is not merely a matter of percentage. According to Schnitzer, it is already difficult to lose more than 10% of one’s weight through diet and exercise alone, especially when knee pain limits movement. “Participants responded remarkably,” he summarized.
Developed by Eli Lilly, retatrutide is delivered as a weekly injection. Scientists from the company also contributed as co-authors on the study, alongside the Northwestern team.
Two thirds of patients relieved where conventional treatments fail
Weight loss is only part of the story. What matters most to people with osteoarthritis is pain relief. And on this front, the results are equally striking: about two-thirds of retatrutide-treated participants reported at least a 50% reduction in their knee pain, versus only 38% in the placebo group.
This difference is far from trivial when you consider what knee osteoarthritis entails in daily life. Walking, climbing stairs, getting up from a chair—simple actions that become real challenges for overweight or obese individuals afflicted by this condition.
Current treatments, by contrast, struggle to provide durable relief. Corticosteroid injections offer only short-term benefits. Physical therapy, topical treatments, opioids, or non-steroidal anti-inflammatory drugs such as ibuprofen and Voltaren remain the most common options, without ever addressing the structural root of the problem.
“A major factor is that you put less strain on your knees, and as a result there is less pain, which allows you to improve your mobility,” Schnitzer explains. Fewer pounds to carry means literally less pressure on the joint with every step.
The benefits extend beyond the knee. Participants also saw their blood pressure drop, their lipid levels fall, and systemic inflammation recede. All of these signals suggest a broader effect on the body, not just a local impact on the painful joint.
To measure this evolution precisely, researchers used the WOMAC pain index, a scale from 0 to 10 assessed during medical visits. Participants also completed a daily evaluation via an app to track their subjective progress over the weeks.
These results, published in the prestigious New England Journal of Medicine, were presented at the American College of Rheumatology annual meeting in Orlando, Florida. Philip Conaghan, a professor at the University of Leeds and co-author of the study, detailed the TRIUMPH-4 trial results there, while the second study, TRIUMPH-1-OA, was the subject of a separate display session on the same day.
The secret to its effectiveness: three hormones activated instead of one
To understand why retatrutide outperforms its predecessors, one must examine its mode of action. Where semaglutide or tirzepatide activate one or two hormonal receptors, retatrutide activates three simultaneously, all tied to hormones naturally present in the body.
Activating a single receptor yields a modest effect. Activating three at once clearly amplifies the result, with weight loss of 20 to 25% observed among study participants.
However, the exact mechanism by which the drug exerts its pain-relieving effect is not fully explained. Schnitzer himself acknowledges: these molecules appear to have notable anti-inflammatory activity, but the share of this effect in the observed relief remains to be clarified, distinct from the simple reduction of load on the joint.
Several questions remain open. People requiring a knee prosthesis were excluded from the trial, and it remains unknown whether retatrutide can slow the progression of osteoarthritis sufficiently to avoid total joint replacement. Likewise, the drug’s effect in non-obese patients has not been tested.
Schnitzer also notes that diet and physical activity remain the foundation of care. These measures are less costly and do not expose patients to the known side effects of GLP-1 agonists, such as gastrointestinal disturbances or loss of muscle mass, an important concern for already fragile knees, since muscles help stabilize the joint.
For the roughly 15 million Americans, about 5% of the population, living with knee osteoarthritis, this medication could nevertheless represent an additional option, provided it receives FDA approval. In the meantime, as Schnitzer emphasizes, these studies mainly pave the way for numerous future investigations to better understand a pathology that remains, in many respects, still mysterious.
Source :
- Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials – Medical Xpress (Northwestern)
- Northwestern University press release – EurekAlert
- Retatrutide reduces knee pain and body weight in osteoarthritis patients – News-Medical (November 8, 2026)
- Schnitzer et al., « Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity », NEJM (manuscript)
Article prepared with the help of AI · Our method